News | August 29, 2025
Sai Life Sciences completes Phase II of production block 11 at Bidar
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Subscribe To Our Newsletter & Stay Updated
